Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

AngioDynamics (market cap $437.6M) reported a solid fiscal Q4 2025 with revenue above estimates, a smaller-than-expected adjusted loss per share and continued strength across Med Tech and Med Device segments; NanoKnife generated $24.5M in fiscal 2025 revenues (Q4 $7.2M) with disposables up 9.6% for the year. Management projects 43.3% growth next year and issued fiscal 2026 guidance that embeds tariff-related costs (gross margin guidance 53.5%–55.5% including tariffs; adj. EBITDA $3.0M–$8.0M, or $7.5M–$10.5M excluding tariffs), while Zacks consensus shows FY26 loss widening to $0.30 and Q1 FY26 revenue consensus of $72.3M (+7.1% YoY). Clinical progress (PRESERVE prostate trial success, Auryon/AlphaVac studies) and a diversified product mix underpin upside, though tariffs and modest negative estimate revisions temper near-term profitability expectations.

Analysis

Market structure: ANGO is a clear beneficiary of recurring disposable revenue from NanoKnife and Auryon — disposables grew ~9.6% in FY25 and NanoKnife revenue was $24.5M (flat YoY) while system placements remain lumpy. Tariffs compress gross margin by ~1.2–3.1 percentage points (Med Tech 59% vs 62.1% excl.), shifting near-term profit mix away from capital sales to higher-margin recurring disposables and increasing working-capital pressure. Competitive winners are niche device vendors with consumable-led business models; losers are players exposed to capital-equipment volatility and tariffed supply chains.

Risk assessment: Key tail risks are reimbursement delays (CPT timing slipping beyond early-2026 for prostate or 2027 for pancreas), clinical setbacks in PRESERVE/AMBITION, or tariff escalation — any of which could cut projected NanoKnife upside by 20–30% versus base. Immediate (days) risk: post-earnings sentiment reversion; short-term (weeks–months): FY26 guidance variance (adjusted EBITDA guide $3–8M vs $7.5–10.5M ex-tariffs); long-term (quarters–years): installed-base ramp and surgeon adoption driving disposables. Hidden dependency: hospital capital budgets and reimbursement cadence drive conversion from system installs to recurring revenue.

Trade implications: Direct play — establish a tactical 2–3% long in ANGO (small-cap risk) with 6–18 month horizon to capture reimbursement and disposables tailwinds, funded with a protective 20% OTM put or buy-protective collar. Pair trade — long ANGO vs short NVST (Envista) or a large-cap dental/implant peer (~1:0.5 dollar-weighted) to isolate small-cap NanoKnife upside versus broader equipment exposure. Options — consider 12–18 month call spreads (buy LEAP calls, sell nearer OTM calls) to cap premium and capture binary reimbursement catalysts; avoid short gamma into earnings.

Contrarian angles: Consensus may underprice tariff permanence and overprice smooth reimbursement timing — the 16% YTD share gain vs industry -11.5% suggests optimism may be front-loaded. Historical parallels: small med-techs with breakthrough designations often trade on binary clinical/reimbursement events; outcomes tend to be amplified (±30–60%). Unintended consequence: faster adoption could stress manufacturing and force price concessions on disposables, compressing margins despite higher revenue.

Key Decisions for Investors

• Establish a 2–3% long equity position in ANGO with a 6–18 month horizon ahead of the PRESERVE reimbursement catalyst (target add if prostate CPT Category I confirmation occurs by Jan 2026); size to fund by trimming 1–2% from non-disposable-heavy med-tech exposure.
• Hedge the position with a protective 20% OTM put (3–6 month) or construct a collar (sell 12–18 month OTM calls) to limit downside while retaining upside to reimbursement milestones; if adjusted EBITDA falls below $3M guide or tariffs widen >100bps versus current guidance, reduce exposure by 50%.
• Implement a pair trade: go long ANGO (2%) and short NVST (1%) to capture small-cap NanoKnife upside while hedging sector beta; rebalance if ANGO outperforms by +30% or if NVST underperforms by -15%.
• Buy a 12–18 month call spread on ANGO (LEAP call/shorter OTM call) sized at 1% notional to leverage upside to clinical/reimbursement wins while capping premium; if PRESERVE reimbursement is delayed beyond Q1 2026, close the spread.
• Reduce exposure by 2–3% to tariff-exposed med-device peers and rotate into disposable-heavy med-tech names (include ANGO, Auryon-exposed stocks) over the next 30–90 days, contingent on tariff policy or supply-chain cost improvements reducing gross-margin headwind by ≥100bps.